STAT+: 5 burning questions on Trump’s latest deals with drugmakers

Agreements leave open questions for patients, companies, and policymakers alike Adobe Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100.Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. The Trump administration on Monday announced a second group of pharmaceutical companies had pledged to lower drug prices to levels comparable to those in other nations. But the details of the deals, which President Trump has touted from the White House as one of the most important breakthroughs in health care, aren’t public. Some key questions remain — including whether all the companies in the second wave would avoid tariffs or otherwise mandatory Medicare drug pricing pilot programs. (The White House did not respond to requests for comment about these questions.) Here are some of the biggest questions about the agreements. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100. National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.